SYN Synthetic Biologics, Inc. Commo

0.81
+0  (0.16%)
Previous Close 0.80
Open 0.84
Price To book 0.00
Market Cap 74.31M
Shares 92,172,000
Volume 396,331
Short Ratio 9.83
Av. Daily Volume 1,186,090

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 2 trial commenced October 2015. 12 week data met endpoints. Phase 2b/3 planned for 1Q 2017.
SYN-010
Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Pending. Partner Meda has received the go-ahead from the FDA to conduct a Phase 2 proof of concept trial
Flupirtine
Fibromyalgia
License terminated following lack of efficacy shown February 2016
Trimesta
Relapsing-remitting MS in women
Phase 2b topline data released January 5, 2017. Primary endpoint met. Phase 3 trial to be initiated end of 2017.
SYN-004
C. difficile Infection

Latest News

  1. Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017
  2. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  3. Synthetic Biologics to Present at the 2017 BIO CEO & Investor Conference
  4. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Prin
  5. Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA
  6. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  7. Synthetic Biologics C. Difficile Drug Trial Succeeds
  8. Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
  9. Synthetic Biologics' C. difficile mid-stage study meets main goal
  10. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  11. Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
  12. Synthetic Biologics to Present at the Biotech Showcase™ 2017 Conference
  13. Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
  14. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Prin
  15. Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences
  16. Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences
  17. Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants
  18. Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants
  19. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta
  20. Nokia, Teva Plunge into Tuesday’s 52-Week Low Club
  21. Synthetic Biologics Prices Secondary Offering
  22. Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants
  23. Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants
  24. Synthetic Biologics Announces Commencement of Public Offering of Common Stock and Warrants
  25. SYNTHETIC BIOLOGICS, INC. Financials
  26. ETF’s with exposure to Synthetic Biologics, Inc. : November 1, 2016
  27. Synthetic Biologics Reports Third Quarter 2016 Operational Highlights and Financial Results
  28. Synthetic Biologics to Report Third Quarter 2016 Operational Highlights and Financial Results on November 1, 2016
  29. Synthetic Biologics Awarded Research Contract from Centers for Disease Control and Prevention (CDC) for Microbiome Assessment and Intervention to Address Antibiotic Resistance
  30. Synthetic Biologics Announces Completion of Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase) for the Prevention of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiot
  31. Synthetic Biologics Reports Second Quarter 2016 Operational Highlights and Financial Results
  32. Synthetic Biologics to Report Second Quarter 2016 Operational Highlights and Financial Results on August 3, 2016
  33. Synthetic Biologics Announces Granting of European and U.S. Composition of Matter Patents for Ribaxamase
  34. Synthetic Biologics Receives USAN Approval for Generic Name Ribaxamase for Phase 2 Drug Candidate SYN-004
  35. Synthetic Biologics to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference
  36. Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
  37. Synthetic Biologics to Host Post-DDW 2016® Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
  38. Synthetic Biologics Announces Positive Topline Results from Second Phase 2a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea
  39. Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
  40. Synthetic Biologics Appoints Deb Mathews, PharmD, as Vice President, Medical Affairs
  41. Synthetic Biologics to Report First Quarter 2016 Operational Highlights and Financial Results on May 5, 2016